Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions

Current Colorectal Cancer Reports - Tập 15 Số 4 - Trang 112-121 - 2019
Saivaishnavi Kamatham1, Faisal Shahjehan2, Pashtoon Murtaza Kasi3
1Visiting Research Fellow, Division of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA
2CORPS Program, Division of Hematology/Oncology, College of Medicine and Oncology, Gastrointestinal Malignancies, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA
3College of Medicine and Oncology, University of Iowa, 200 Hawkins, Iowa Cit, IA, 52242, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

Koopman M, Kortman GAM, Mekenkamp L, Ligtenberg MJL, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266–73.

Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322–30. https://doi.org/10.1158/1078-0432.CCR-14-0332 .

Tougeron D, Cohen R, Sueur B, Sefrioui D, Gentilhomme L, Lecomte T, et al. 533PA large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. Ann Oncol. 2017;28(suppl_5):v158–208. https://doi.org/10.1093/annonc/mdx393 .

Nebot-Bral L, Coutzac C, Kannouche PL, Chaput N. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? Bull Cancer. 2019;106(2):105–13. https://doi.org/10.1016/j.bulcan.2018.08.007 .

Cohen R, Pellat A, Boussion H, Svrcek M, Lopez-Trabada D, Trouilloud I, et al. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. Bull Cancer. 2019;106(2):137–42. https://doi.org/10.1016/j.bulcan.2018.09.004 .

Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, et al. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. NCCN Guidelines Version 1.2018 Genetic/Familial High-Risk Assessment: Colorectal. Cancer. 2019; 15;125(2):278–289. https://doi.org/10.1002/cncr.31795 .

Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51.

NCCN Guidelines Version 1.2018 Genetic/Familial High-Risk Assessment: Colorectal. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf .

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

O’Neil BH, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12(12):e0189848.

•• Diaz LA, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol. 2017;35(15_suppl):3071–1. The early results of the KEYNOTE-164 study affirmed the robust antitumor activity of pembrolizumab in patients with pretreated MSI-H colorectal cancer.

Overman MJ, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34(15_suppl):3501–1.

•• Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9. CheckMate-142 is the largest single-study report of combination immunotherpy with nivolumab and ipilimumab demonstrating high response rate and safety profile.

•• Lenz HJ, van Cutsem E, Limon ML, Wong KY, Hendlisz A, Aglietta M, et al. LBA18_PR durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Ann Oncol. 2018;29(Suppl 8). This study reports the first results of clinical efficacy and safety of nivolumab plus a low dose of ipilimumab as a new first-line therapy for dMMR/MSI-H mCRC.

•• Chalabi M, Fanchi LF, Van den Berg JG, Beets GL, Lopez-Yurda M, Aalbers AG, et al. LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer. Ann Oncol. 2018;29(suppl_8). https://doi.org/10.1093/annonc/mdy424.047 . The first study to suggest short-term neoadjuvant nivolumab plus ipilimumab combination therapy has the potential to change current standard of care in dMMR early satge colon cancers.

NCCN Guidelines Version 2.2019 Colon Cancer. Systemic therapy for advanced or metastatic disease - chemotherapy regimens. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf .

• Bendell J, Ciardiello F, Tabernero J, Tebbutt N, Eng C, Di Bartolomeo M, et al. LBA-004 efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann Oncol. 2018;29(suppl_5). https://doi.org/10.1093/annonc/mdy208.003 . A global, multi-center study whose primary analysis validated that atezolizumab plus cobimetinib combination or atezolizumab monotherapy had no statistically significant outcomes in efficay for MSS mCRC.

Chen EX, Jonker DJ, Kennecke HF, Berry SR, Couture F, Ahmad CE, et al. 26 trial: a phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). J Clin Oncol. 2019;37(4_suppl):481–1. https://doi.org/10.1200/JCO.2019.37.4 .

Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65.

Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K.Wansley E, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–71.

NIH U.S. National Library of Medicine ClinicalTrials.gov. Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors. ClinicalTrials.gov Identifier: NCT01876511. https://clinicaltrials.gov/ct2/show/NCT01876511 .

NIH U.S. National Library of Medicine ClinicalTrials.gov. Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) ClinicalTrials.gov Identifier: NCT02460198. https://clinicaltrials.gov/ct2/show/NCT02460198 .

• NIH U.S. National Library of Medicine ClinicalTrials.gov. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) ClinicalTrials.gov Identifier: NCT02563002. https://clinicaltrials.gov/ct2/show/NCT02563002 . An ongoing clinical trial that compares progression free survival and overall survival in dMMR/MSI-H stage IV CRC patients receiving pembrolizumab vs those receiving standard chemotherapy.

• NIH U.S. National Library of Medicine ClinicalTrials.gov. Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer ClinicalTrials.gov Identifier: NCT02873195. https://clinicaltrials.gov/ct2/show/NCT02873195 . BACCI study is an ongoing clinical trial to estimate the efficacy of atezolizumab plus capecitabine/bevacizumab therapy in refractory mCRC patients.

NIH U.S. National Library of Medicine ClinicalTrials.gov. An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) ClinicalTrials.gov Identifier: NCT03414983. https://clinicaltrials.gov/ct2/show/NCT03414983 .

•• NIH U.S. National Library of Medicine ClinicalTrials.gov. Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer ClinicalTrials.gov Identifier: NCT02997228. https://clinicaltrials.gov/ct2/show/NCT02997228 . This phase III randomized clinical trial is currently recruiting patients to study the efficacy of atezolizumab plus combination chemotherapy/bevacizumab as first line tresatment of patients with dMMR mCRC.

•• NIH U.S. National Library of Medicine ClinicalTrials.gov. Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair ClinicalTrials.gov Identifier: NCT02912559. https://clinicaltrials.gov/ct2/show/NCT02912559 . Atomic study is an ongoing phase III clinical trial to assess efficacy of combination chemotherapy and atezolizumab in patients with stage III dMMR colon cancer.

NIH U.S. National Library of Medicine ClinicalTrials.gov. Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX) ClinicalTrials.gov Identifier: NCT02777710. https://clinicaltrials.gov/ct2/show/NCT02777710 .

NIH U.S. National Library of Medicine ClinicalTrials.gov. Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers. ClinicalTrials.gov Identifier: NCT02484404. https://clinicaltrials.gov/ct2/show/NCT02484404 .

• NIH U.S. National Library of Medicine ClinicalTrials.gov. Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI). ClinicalTrials.gov Identifier: NCT03608046. https://clinicaltrials.gov/ct2/show/NCT03608046 . A new clinical trial to assess tumor response rate in MSI stable metastatic colorectal cancer patients on treatment with avelumab combined with cetuximab and irinotecan.

•• NIH U.S. National Library of Medicine ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC). ClinicalTrials.gov Identifier: NCT03555149. https://clinicaltrials.gov/ct2/show/NCT03555149 . Morpheus-CRC is a phase Ib/II, open-label, multicenter, randomized study designed to evaluate safety and efficacay of multiple immunotherapy based therapy combinations.

NIH U.S. National Library of Medicine ClinicalTrials.gov. An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9). ClinicalTrials.gov Identifier: NCT03377361. https://clinicaltrials.gov/ct2/show/NCT03377361 .

NIH U.S. National Library of Medicine ClinicalTrials.gov. Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer ClinicalTrials.gov Identifier: NCT03711058. https://clinicaltrials.gov/ct2/show/NCT03711058 .

NIH U.S. National Library of Medicine ClinicalTrials.gov. Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer ClinicalTrials.gov Identifier: NCT03642067. https://clinicaltrials.gov/ct2/show/NCT03642067 .

•• NIH U.S. National Library of Medicine ClinicalTrials.gov. Synergism of Immunomodulation and Tumor Ablation (ILOC) ClinicalTrials.gov Identifier: NCT03101475. https://clinicaltrials.gov/ct2/show/NCT03101475 . ILOC- a phase II single arm, multicenter trial to study the synergism of immunotherapy (durvalumab, tremelimumab) and local tumor ablation with radiofrequency ablation (RFA) or stereotactic body radiation therapy (SBRT) in colorectal cancer with liver metastases.

•• NIH U.S. National Library of Medicine ClinicalTrials.gov. Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases ClinicalTrials.gov Identifier: NCT03802747. https://clinicaltrials.gov/ct2/show/NCT03802747 . A new phse I clinical trial to evaluate the efficacy of combination of dual immune checkpoint blockade (durvalumab, Tremelimumab) plus Yttrium-90 (Y-90) radioembolization & stereotactic body radiation therapy (SBRT) in refractory metastatic MSS colorectal cancer with liver metastases.

NIH U.S. National Library of Medicine ClinicalTrials.gov. Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer ClinicalTrials.gov Identifier: NCT03507699. https://clinicaltrials.gov/ct2/show/NCT03507699 .

NIH U.S. National Library of Medicine ClinicalTrials.gov. Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer ClinicalTrials.gov Identifier: NCT03104439. https://clinicaltrials.gov/ct2/show/NCT03104439 .

•• NIH U.S. National Library of Medicine ClinicalTrials.gov. QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC ClinicalTrials.gov Identifier: NCT03169777. https://clinicaltrials.gov/ct2/show/NCT03169777 . QUILT-3.050 - phase 1b/2 study to assess the safety and efficacy of NANT colorectal cancer vaccine: combination immunotherapy in recurrent or metastatic colorectal cancer.

NIH U.S. National Library of Medicine ClinicalTrials.gov. CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors ClinicalTrials.gov Identifier: NCT02757391. https://clinicaltrials.gov/ct2/show/NCT02757391 .

• NIH U.S. National Library of Medicine ClinicalTrials.gov. Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer ClinicalTrials.gov Identifier: NCT03800602. https://clinicaltrials.gov/ct2/show/NCT03800602 . A phse II trial to determine the efficacy of nivolumab and metformin in treatment refractory microsatellite stable (MSS) colorectal cancer.

Fletcher R, Wang YJ, Schoen RE, Finn OJ, Yu J, Zhang L. Colorectal cancer prevention: immune modulation taking the stage. Biochim Biophys Acta Rev Cancer. 2018;1869(2):138–48.

Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2013;6(1):18–26.

Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother. 2013;62(8):1293–301.

Koblansky AA, Truax AD, Liu R, Montgomery SA, Ding S, Wilson JE, et al. The innate immune receptor NLRX1 functions as a tumor suppressor by reducing colon tumorigenesis and key tumor-promoting signals. Cell Rep. 2016;14(11):2562–75.

Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162(6):1257–70.